Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of AD-101 vs Raloxifene in Healthy Volunteers
NCT03764462Phase 1Completed
- Sponsor
- Addpharma, Inc.
- Start
- Dec 2018
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of Ismidenon in osteoporosis, sponsored by Addpharma, Inc. Primary endpoints: Peak Plasma Concentration and Area under the curve in time plot. Started Dec 2018; status: completed.
02
Drugs
Ismidenon
03
Conditions
osteoporosis
Beyond the preview
Go deeper on NCT03764462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03764462.